微导管在老年肝癌患者介入治疗中的应用

目的探讨微导管在老年原发性肝癌患者肝动脉介入治疗中的应用价值。方法回顾性分析2009年1月至2011年12月江苏省泰州市人民医院诊治的119例60岁以上原发性肝癌患者，其中78例行微导管肝动脉介入治疗（微导管组），41例行普通导管介入治疗（对照组），比较两组的疗效、不良反应及生存率。结果微导管组临床治愈和明显好转者共69例（占88．46％）；其半年、1年、2年生存率分别是80．77％（63／78）、58．97％（46，78）、28．21％（22／78）。对照组临床治愈和明显好转者共31例，（占75．61％）；其半年、1年、2年生存率分别是75．61％（31／41）、43．90％（18／41）、17．07％（7／41）。微导管组临床治愈和明显好转率及1、2年生存率均高于对照组（P均〈0．05），且其栓塞后反应及血管内膜损伤明显低于对照组（P均〈0．05）。结论应用微导管对老年原发性肝癌患者行介入治疗能增强疗效，降低术后不良反应的发生率，延长患者生存期。

Application of micro-catheter in interventional embolization treatment on primary hepatocellular carcinoma in elderly patients

Objective To investigate the application of micro-catheter in interventional embolization treatment on primary hepatocellular carcinoma(HCC) in elderly patients.Methods A total of 119 patients over 60 years old with HCC hospitalized in People’s Hospital of Taizhou from January 2009 to December 2011 were entrolled in the study.All the cases were divided into two groups,78 cases(micro-catheter group) undergone micro-catheter embolization treatment,and 41 cases(control group) received conventional catheter embolization therapy.The therapeutic effect,side effect and survival rate were compared between the two groups.Results Sixty-nine(88.46%) cases in the micro-catheter group were clinically "cured" or obviously improved,and the 6-month,1-and 2-year survival rates were 75.64%,58.97% and 14.1%,respectively.While in the control group,31(75.61%) cases were markedly improved,and the 6-month,1-and 2-year survival rates were 75.61%,39.02% and 7.32%,respectively.Compared with the control group,the micro-catheter group has a higher cure rate and higher 1-and 2-year survival rates(all P < 0.05);furthermore,its vascular intimal injury was significantly reduced(P < 0.05).ConclusionThe application of micro-catheter in interventional embolization treatment can greatly improve the clinically cure rate of HCC,decrease the side effects of the procedure and prolong the survival of elderly patients with HCC.